A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA) Read more about A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Real-world evidence Non-Interventional proSpective study of kisqaLi (Ribociclib) Effectiveness and safety in patients with HR+/HER2- early Breast Cancer in Saudi Arabia Read more about Real-world evidence Non-Interventional proSpective study of kisqaLi (Ribociclib) Effectiveness and safety in patients with HR+/HER2- early Breast Cancer in Saudi Arabia
Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia Read more about Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi-Center, Open Label, Single Arm, Phase II, PET-Adaptive Study Read more about Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi-Center, Open Label, Single Arm, Phase II, PET-Adaptive Study
The Effect of Empagliflozin (SGLT2 Inhibitor) in Pulmonary Arterial Hypertension: A Single Arm Prospective Interventional Study Read more about The Effect of Empagliflozin (SGLT2 Inhibitor) in Pulmonary Arterial Hypertension: A Single Arm Prospective Interventional Study
Phase II, Prospective, Randomized, placebo-controlled, double-blind study.Evaluation of Phytochemical properties and Phytotherapeutic Potential of Boswellia carteri Birdw. in Psoriasis Read more about Phase II, Prospective, Randomized, placebo-controlled, double-blind study.Evaluation of Phytochemical properties and Phytotherapeutic Potential of Boswellia carteri Birdw. in Psoriasis
Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours Read more about Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours
Modified Quadruple Therapy Regimen for Helicobacter pylori Eradication – A Prospective Randomized Controlled Trial Read more about Modified Quadruple Therapy Regimen for Helicobacter pylori Eradication – A Prospective Randomized Controlled Trial
Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi- Center, Open-Label, Single-Arm, Phase II, PET-Adaptive Study Read more about Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi- Center, Open-Label, Single-Arm, Phase II, PET-Adaptive Study
A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptorpositive/HER2-negative inoperable locally advanced or metastatic breast cancer – RIGHT Choice Study. Read more about A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptorpositive/HER2-negative inoperable locally advanced or metastatic breast cancer – RIGHT Choice Study.
